Imatinib is the first-line recommended drug for the treatment of Philadelphia chromosome-positive chronic granulocytic leukemia. In clinical practice, the dosage of imatinib varies according to the different stages of chronic granulocytic leukemia, generally 400 mg/d in the chronic phase, 600 mg/d in the accelerated phase, and 600-800 mg/d in the acute phase. imatinib has significant toxic side effects, often causing adverse effects such as headache, abdominal pain, edema, etc. Taking imatinib can also A decrease in the number of white blood cells and platelets can occur. If the white blood cell count is less than 2000/mL and the platelet count is less than 50,000/mL, imatinib requires a dose reduction, commonly 300 mg/d.